294,392 Shares in Humacyte, Inc. $HUMA Purchased by Nuveen LLC

Key Points

• Nuveen LLC acquired a new stake in Humacyte, Inc. by purchasing 294,392 shares valued at approximately $502,000, representing around 0.19% ownership of the company.
• Humacyte's stock has a consensus rating of "Buy" with a target price averaging $9.75, despite recent downgrades by some analysts.
• The company's recent earnings report showed a loss of ($0.24) per share, which missed analysts' expectations, alongside a revenue of just $0.30 million.

Nuveen LLC acquired a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 294,392 shares of the company's stock, valued at approximately $502,000. Nuveen LLC owned approximately 0.19% of Humacyte at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Woodline Partners LP lifted its position in Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock valued at $14,386,000 after acquiring an additional 2,000,268 shares during the last quarter. Bank of America Corp DE increased its position in shares of Humacyte by 160.2% during the fourth quarter. Bank of America Corp DE now owns 597,319 shares of the company's stock worth $3,016,000 after purchasing an additional 367,720 shares in the last quarter. Waverly Advisors LLC lifted its holdings in shares of Humacyte by 331.9% in the 4th quarter. Waverly Advisors LLC now owns 274,579 shares of the company's stock valued at $1,387,000 after purchasing an additional 211,009 shares during the last quarter. Pamalican Asset Management Ltd purchased a new position in Humacyte during the 1st quarter worth approximately $341,000. Finally, CenterBook Partners LP increased its position in Humacyte by 11.1% during the first quarter. CenterBook Partners LP now owns 1,422,512 shares of the company's stock worth $2,425,000 after buying an additional 142,673 shares during the period. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Activity

In related news, Director Brady W. Dougan sold 591,685 shares of the business's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 591,685 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Insiders sold 4,482,090 shares of company stock valued at $7,466,382 in the last quarter. Company insiders own 5.10% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. TD Cowen decreased their price objective on Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a report on Tuesday, August 12th. Barclays started coverage on shares of Humacyte in a research report on Wednesday, August 27th. They set an "overweight" rating and a $3.50 price objective on the stock. HC Wainwright reduced their target price on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Benchmark decreased their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Monday, August 11th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $9.75.

Humacyte Stock Performance

Shares of HUMA stock traded down $0.02 during trading hours on Wednesday, reaching $1.48. 2,028,870 shares of the company's stock were exchanged, compared to its average volume of 3,775,775. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The company's 50 day moving average is $2.03 and its two-hundred day moving average is $2.14. The company has a market cap of $234.39 million, a P/E ratio of -3.29 and a beta of 1.87. Humacyte, Inc. has a 1 year low of $1.15 and a 1 year high of $6.77.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The business had revenue of $0.30 million during the quarter, compared to analysts' expectations of $0.94 million. Equities research analysts anticipate that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.